<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153321</url>
  </required_header>
  <id_info>
    <org_study_id>D3320C00001</org_study_id>
    <secondary_id>2010-020141-26</secondary_id>
    <nct_id>NCT01153321</nct_id>
  </id_info>
  <brief_title>Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of
      patients with mild COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Monocyte Count in BAL Post-LPS Challenge</measure>
    <time_frame>Day 11</time_frame>
    <description>Monocyte count in BAL post-LPS challenge (Day 11)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Neutrophils in Biopsy Sample (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Pre-challenge = Day 11. Biopsies taken from left lingula. Cells counted in subepithelium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Macrophages in Biopsy Sample (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD45+ in Biopsy Sample (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3+ in Biopsy Sample (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy PAS Reaction Grade (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Biopsies stained using PAS method. Graded on subjective scale (1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Epithelium Grade (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Biopsies (from right middle lobe) were assessed for routine histopathology. Epithelial morphology was graded on subjective scale from 1 to 5. 1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge eosinophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge lymphocyte differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge neutrophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrophages in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge macrophage differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF α Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge TNF α concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCL2 Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge CCL2 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1β Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge IL-1β concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge IL-6 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8 Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge IL 8 concentration in BAL. LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RANTES Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge RANTES concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SP-D Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge SP-D concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAA Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>SAA concentration in blood pre-LPS challenge (Day 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAA Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>SAA concentration in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCL2 Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>CCL2 concentration in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCL2 Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>CCL2 concentration in blood post-LPS challenge (Day 11).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1β Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>IL-1β concentration in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1β Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>IL-1β concentration in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>IL-6 concentration in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>IL-6 concentration in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8 Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>IL-8 concentration in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8 Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>day 11</time_frame>
    <description>IL-8 concentration in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>TNF-α concentration in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>TNF-α concentration in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SP-D Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>SP-D concentration in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SP-D Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>SP-D concentration in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CC16 Concentration in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>CC16 concentration in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CC16 Concentration in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>CC16 concentration in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophils in Blood (Pre-LPS Challenge)</measure>
    <time_frame>day 10</time_frame>
    <description>Basophils in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophils in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Basophils in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>Eosinophils in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Eosinophils in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>Lymphocytes in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Lymphocytes in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>Monocytes in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Monocytes in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils in Blood (Pre-LPS Challenge)</measure>
    <time_frame>Day 10</time_frame>
    <description>Neutrophils in blood pre-LPS challenge (Day 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils in Blood (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Neutrophils in blood post-LPS challenge (Day 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of AZD2423 at Steady State</measure>
    <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
    <description>Steady state pharmacokinetic (PK) profile measured on Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of AZD2423 at Steady State</measure>
    <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
    <description>Steady state PK profile measured on Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero to 24 Hours (AUC(0-24)) of AZD2423 at Steady State</measure>
    <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
    <description>Steady state PK profile measured on Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero to 8 Hours (AUC(0-8)) of AZD2423 at Steady State</measure>
    <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
    <description>Steady state PK profile measured on Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Treatment-related Changes in Laboratory Variables Other Than Monocytes</measure>
    <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Vital Signs</measure>
    <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Variables</measure>
    <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Physical Examination</measure>
    <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-related or Clinically Relevant Changes in Spirometry (Forced Expiratory Volume in 1 Second [FEV1], Forced Vital Capacity [FVC] Pre-bronchodilator)</measure>
    <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CC16 Concentration in BAL (Post-LPS Challenge)</measure>
    <time_frame>Day 11</time_frame>
    <description>Post-LPS challenge CC16 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Lung Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2423</intervention_name>
    <description>100mg Oral dose od</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2423 Placebo</intervention_name>
    <description>Oral dose od</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only women of non-child bearing potential are included in the study i.e. women who are
             permanently or surgically sterilised or post menopausal.

          -  ≥ 40 years of age at Visit 1

          -  Clinical diagnosis of COPD (GOLD stage 1)

          -  FEV1 ≥ 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1)

          -  FEV1/FVC &lt;70% post-bronchodilator at Visit 1 (GOLD stage 1)

        Exclusion Criteria:

          -  Any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk or influence the way the drug works

          -  Any clinically relevant abnormal findings in physical examination, blood or urine test
             results, vital signs or ECG at Visit 1 that may put the subject at risk during the
             study, affect their ability or take part or influence the results of the study

          -  A past history or current indication of renal (kidney) failure

          -  Subjects at risk of active tuberculosis or of disease reactivation

          -  Subjects who have had any clinically significant illness within 4 weeks before Visit 2
             (start of treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Larsson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=206&amp;filename=CSR-D3320C00001.pdf</url>
    <description>D3320C00001 Clinical Study Report Synopsis</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=206&amp;filename=D3320C00001.pdf</url>
    <description>D3320C00001 CSR Synopsis</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <results_first_submitted>July 15, 2013</results_first_submitted>
  <results_first_submitted_qc>October 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2014</results_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory disease</keyword>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single centre study conducted at a medical research centre in Germany. The first patient was enrolled on 01 October 2010 and the last patient last visit was on 28 July 2011.
A total of 71 subjects were enrolled to get 44 subjects that fulfilled the inclusion criterions.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD2423</title>
          <description>Two 50 mg AZD2423 tablets, once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to match AZD2423 tablets, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Development of study withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD2423</title>
          <description>Two 50 mg AZD2423 tablets, once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to match AZD2423 tablets, once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="7.6"/>
                    <measurement group_id="B2" value="54.1" spread="8.1"/>
                    <measurement group_id="B3" value="53" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Monocyte Count in BAL Post-LPS Challenge</title>
        <description>Monocyte count in BAL post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Monocyte Count in BAL Post-LPS Challenge</title>
          <description>Monocyte count in BAL post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398" spread="1.276"/>
                    <measurement group_id="O2" value="514.4" spread="1.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Neutrophils in Biopsy Sample (Post-LPS Challenge)</title>
        <description>Pre-challenge = Day 11. Biopsies taken from left lingula. Cells counted in subepithelium.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Neutrophils in Biopsy Sample (Post-LPS Challenge)</title>
          <description>Pre-challenge = Day 11. Biopsies taken from left lingula. Cells counted in subepithelium.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
          <units>cells/mm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="1.218"/>
                    <measurement group_id="O2" value="34.04" spread="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Macrophages in Biopsy Sample (Post-LPS Challenge)</title>
        <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Macrophages in Biopsy Sample (Post-LPS Challenge)</title>
          <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
          <units>cells/mm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.44" spread="1.233"/>
                    <measurement group_id="O2" value="41.17" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD45+ in Biopsy Sample (Post-LPS Challenge)</title>
        <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CD45+ in Biopsy Sample (Post-LPS Challenge)</title>
          <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
          <units>cells/mm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.7" spread="1.133"/>
                    <measurement group_id="O2" value="203.2" spread="1.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD3+ in Biopsy Sample (Post-LPS Challenge)</title>
        <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CD3+ in Biopsy Sample (Post-LPS Challenge)</title>
          <description>Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Six patients had missing observations.</population>
          <units>cells/mm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.84" spread="1.212"/>
                    <measurement group_id="O2" value="81.1" spread="1.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy PAS Reaction Grade (Post-LPS Challenge)</title>
        <description>Biopsies stained using PAS method. Graded on subjective scale (1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells).</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Thirteen patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy PAS Reaction Grade (Post-LPS Challenge)</title>
          <description>Biopsies stained using PAS method. Graded on subjective scale (1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells).</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Thirteen patients had missing observations.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="0.415"/>
                    <measurement group_id="O2" value="2.5" spread="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy Epithelium Grade (Post-LPS Challenge)</title>
        <description>Biopsies (from right middle lobe) were assessed for routine histopathology. Epithelial morphology was graded on subjective scale from 1 to 5. 1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Thirteen patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy Epithelium Grade (Post-LPS Challenge)</title>
          <description>Biopsies (from right middle lobe) were assessed for routine histopathology. Epithelial morphology was graded on subjective scale from 1 to 5. 1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Thirteen patients had missing observations.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.32"/>
                    <measurement group_id="O2" value="2.29" spread="0.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophils in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge eosinophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Five patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophils in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge eosinophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Five patients had missing observations.</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.15" spread="1.264"/>
                    <measurement group_id="O2" value="61.35" spread="1.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocytes in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge lymphocyte differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocytes in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge lymphocyte differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.7" spread="1.242"/>
                    <measurement group_id="O2" value="161.7" spread="1.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophils in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge neutrophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophils in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge neutrophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2063" spread="1.3"/>
                    <measurement group_id="O2" value="1890" spread="1.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Macrophages in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge macrophage differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Macrophages in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge macrophage differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771.1" spread="1.181"/>
                    <measurement group_id="O2" value="917.7" spread="1.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNF α Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge TNF α concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>TNF α Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge TNF α concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread="1.134"/>
                    <measurement group_id="O2" value="3.11" spread="1.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CCL2 Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge CCL2 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CCL2 Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge CCL2 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.47" spread="1.128"/>
                    <measurement group_id="O2" value="46.25" spread="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-1β Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge IL-1β concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-1β Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge IL-1β concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.15"/>
                    <measurement group_id="O2" value="1.05" spread="1.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6 Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge IL-6 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6 Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge IL-6 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.97" spread="1.213"/>
                    <measurement group_id="O2" value="19.76" spread="1.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-8 Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge IL 8 concentration in BAL. LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-8 Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge IL 8 concentration in BAL. LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.5" spread="1.114"/>
                    <measurement group_id="O2" value="207.8" spread="1.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RANTES Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge RANTES concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>RANTES Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge RANTES concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="1.16"/>
                    <measurement group_id="O2" value="4.82" spread="1.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SP-D Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge SP-D concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>SP-D Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge SP-D concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. One patient had missing observations.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637.3" spread="1.081"/>
                    <measurement group_id="O2" value="799.1" spread="1.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAA Concentration in Blood (Pre-LPS Challenge)</title>
        <description>SAA concentration in blood pre-LPS challenge (Day 10).</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>SAA Concentration in Blood (Pre-LPS Challenge)</title>
          <description>SAA concentration in blood pre-LPS challenge (Day 10).</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2312" spread="1.168"/>
                    <measurement group_id="O2" value="2510" spread="1.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAA Concentration in Blood (Post-LPS Challenge)</title>
        <description>SAA concentration in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>SAA Concentration in Blood (Post-LPS Challenge)</title>
          <description>SAA concentration in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18615" spread="1.201"/>
                    <measurement group_id="O2" value="16312" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CCL2 Concentration in Blood (Pre-LPS Challenge)</title>
        <description>CCL2 concentration in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CCL2 Concentration in Blood (Pre-LPS Challenge)</title>
          <description>CCL2 concentration in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1212" spread="1.041"/>
                    <measurement group_id="O2" value="323.4" spread="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CCL2 Concentration in Blood (Post-LPS Challenge)</title>
        <description>CCL2 concentration in blood post-LPS challenge (Day 11).</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CCL2 Concentration in Blood (Post-LPS Challenge)</title>
          <description>CCL2 concentration in blood post-LPS challenge (Day 11).</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1182" spread="1.061"/>
                    <measurement group_id="O2" value="292.9" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-1β Concentration in Blood (Pre-LPS Challenge)</title>
        <description>IL-1β concentration in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-1β Concentration in Blood (Pre-LPS Challenge)</title>
          <description>IL-1β concentration in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="1.055"/>
                    <measurement group_id="O2" value="1.14" spread="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-1β Concentration in Blood (Post-LPS Challenge)</title>
        <description>IL-1β concentration in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-1β Concentration in Blood (Post-LPS Challenge)</title>
          <description>IL-1β concentration in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="1.017"/>
                    <measurement group_id="O2" value="1.12" spread="1.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6 Concentration in Blood (Pre-LPS Challenge)</title>
        <description>IL-6 concentration in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6 Concentration in Blood (Pre-LPS Challenge)</title>
          <description>IL-6 concentration in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="1.087"/>
                    <measurement group_id="O2" value="2.55" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6 Concentration in Blood (Post-LPS Challenge)</title>
        <description>IL-6 concentration in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6 Concentration in Blood (Post-LPS Challenge)</title>
          <description>IL-6 concentration in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="1.215"/>
                    <measurement group_id="O2" value="2.87" spread="1.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-8 Concentration in Blood (Pre-LPS Challenge)</title>
        <description>IL-8 concentration in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-8 Concentration in Blood (Pre-LPS Challenge)</title>
          <description>IL-8 concentration in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37" spread="1.059"/>
                    <measurement group_id="O2" value="9.47" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-8 Concentration in Blood (Post-LPS Challenge)</title>
        <description>IL-8 concentration in blood post-LPS challenge (Day 11)</description>
        <time_frame>day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IL-8 Concentration in Blood (Post-LPS Challenge)</title>
          <description>IL-8 concentration in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.14" spread="1.193"/>
                    <measurement group_id="O2" value="8.85" spread="1.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNF-α Concentration in Blood (Pre-LPS Challenge)</title>
        <description>TNF-α concentration in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>TNF-α Concentration in Blood (Pre-LPS Challenge)</title>
          <description>TNF-α concentration in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.07" spread="1.095"/>
                    <measurement group_id="O2" value="12.55" spread="1.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNF-α Concentration in Blood (Post-LPS Challenge)</title>
        <description>TNF-α concentration in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>TNF-α Concentration in Blood (Post-LPS Challenge)</title>
          <description>TNF-α concentration in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.11" spread="1.09"/>
                    <measurement group_id="O2" value="11.19" spread="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SP-D Concentration in Blood (Pre-LPS Challenge)</title>
        <description>SP-D concentration in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>SP-D Concentration in Blood (Pre-LPS Challenge)</title>
          <description>SP-D concentration in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.8" spread="1.043"/>
                    <measurement group_id="O2" value="181.6" spread="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SP-D Concentration in Blood (Post-LPS Challenge)</title>
        <description>SP-D concentration in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>SP-D Concentration in Blood (Post-LPS Challenge)</title>
          <description>SP-D concentration in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.8" spread="1.041"/>
                    <measurement group_id="O2" value="185.6" spread="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CC16 Concentration in Blood (Pre-LPS Challenge)</title>
        <description>CC16 concentration in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Three patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CC16 Concentration in Blood (Pre-LPS Challenge)</title>
          <description>CC16 concentration in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Three patients had missing observations.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.2" spread="1.034"/>
                    <measurement group_id="O2" value="125.4" spread="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CC16 Concentration in Blood (Post-LPS Challenge)</title>
        <description>CC16 concentration in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Five patients had missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CC16 Concentration in Blood (Post-LPS Challenge)</title>
          <description>CC16 concentration in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge. Five patients had missing observations.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.7" spread="1.039"/>
                    <measurement group_id="O2" value="121.6" spread="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basophils in Blood (Pre-LPS Challenge)</title>
        <description>Basophils in blood pre-LPS challenge (Day 10)</description>
        <time_frame>day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Basophils in Blood (Pre-LPS Challenge)</title>
          <description>Basophils in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="1.106"/>
                    <measurement group_id="O2" value="3.06" spread="1.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basophils in Blood (Post-LPS Challenge)</title>
        <description>Basophils in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Basophils in Blood (Post-LPS Challenge)</title>
          <description>Basophils in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="1.145"/>
                    <measurement group_id="O2" value="3.02" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophils in Blood (Pre-LPS Challenge)</title>
        <description>Eosinophils in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophils in Blood (Pre-LPS Challenge)</title>
          <description>Eosinophils in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.19" spread="1.161"/>
                    <measurement group_id="O2" value="17.32" spread="1.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophils in Blood (Post-LPS Challenge)</title>
        <description>Eosinophils in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophils in Blood (Post-LPS Challenge)</title>
          <description>Eosinophils in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="1.092"/>
                    <measurement group_id="O2" value="19.8" spread="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocytes in Blood (Pre-LPS Challenge)</title>
        <description>Lymphocytes in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocytes in Blood (Pre-LPS Challenge)</title>
          <description>Lymphocytes in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.6" spread="1.035"/>
                    <measurement group_id="O2" value="215.2" spread="1.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocytes in Blood (Post-LPS Challenge)</title>
        <description>Lymphocytes in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocytes in Blood (Post-LPS Challenge)</title>
          <description>Lymphocytes in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.7" spread="1.043"/>
                    <measurement group_id="O2" value="198.8" spread="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocytes in Blood (Pre-LPS Challenge)</title>
        <description>Monocytes in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes in Blood (Pre-LPS Challenge)</title>
          <description>Monocytes in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.17" spread="1.13"/>
                    <measurement group_id="O2" value="51.11" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocytes in Blood (Post-LPS Challenge)</title>
        <description>Monocytes in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes in Blood (Post-LPS Challenge)</title>
          <description>Monocytes in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.99" spread="1.053"/>
                    <measurement group_id="O2" value="63.33" spread="1.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophils in Blood (Pre-LPS Challenge)</title>
        <description>Neutrophils in blood pre-LPS challenge (Day 10)</description>
        <time_frame>Day 10</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophils in Blood (Pre-LPS Challenge)</title>
          <description>Neutrophils in blood pre-LPS challenge (Day 10)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.6" spread="1.055"/>
                    <measurement group_id="O2" value="464.4" spread="1.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophils in Blood (Post-LPS Challenge)</title>
        <description>Neutrophils in blood post-LPS challenge (Day 11)</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophils in Blood (Post-LPS Challenge)</title>
          <description>Neutrophils in blood post-LPS challenge (Day 11)</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>x10^4 cells/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.4" spread="1.083"/>
                    <measurement group_id="O2" value="514.7" spread="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of AZD2423 at Steady State</title>
        <description>Steady state pharmacokinetic (PK) profile measured on Day 10</description>
        <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
        <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of AZD2423 at Steady State</title>
          <description>Steady state pharmacokinetic (PK) profile measured on Day 10</description>
          <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.77" lower_limit="94.3" upper_limit="655.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax) of AZD2423 at Steady State</title>
        <description>Steady state PK profile measured on Day 10</description>
        <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
        <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of AZD2423 at Steady State</title>
          <description>Steady state PK profile measured on Day 10</description>
          <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero to 24 Hours (AUC(0-24)) of AZD2423 at Steady State</title>
        <description>Steady state PK profile measured on Day 10</description>
        <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
        <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero to 24 Hours (AUC(0-24)) of AZD2423 at Steady State</title>
          <description>Steady state PK profile measured on Day 10</description>
          <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1454.14" lower_limit="872.7" upper_limit="2259.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero to 8 Hours (AUC(0-8)) of AZD2423 at Steady State</title>
        <description>Steady state PK profile measured on Day 10</description>
        <time_frame>Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose</time_frame>
        <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero to 8 Hours (AUC(0-8)) of AZD2423 at Steady State</title>
          <description>Steady state PK profile measured on Day 10</description>
          <population>All 22 patients who received AZD2423 provided at least one plasma sample and were included in the PK analysis although only 21 patients were included in the evaluation of PK at day 10, one patient had been discontinued due to an AE.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="801.25" lower_limit="488.5" upper_limit="1182.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Treatment-related Changes in Laboratory Variables Other Than Monocytes</title>
        <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Treatment-related Changes in Laboratory Variables Other Than Monocytes</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Changes in Vital Signs</title>
        <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Changes in Vital Signs</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Variables</title>
        <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Variables</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Changes in Physical Examination</title>
        <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Changes in Physical Examination</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-related or Clinically Relevant Changes in Spirometry (Forced Expiratory Volume in 1 Second [FEV1], Forced Vital Capacity [FVC] Pre-bronchodilator)</title>
        <time_frame>up to 47 days (visit 1 to visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related or Clinically Relevant Changes in Spirometry (Forced Expiratory Volume in 1 Second [FEV1], Forced Vital Capacity [FVC] Pre-bronchodilator)</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CC16 Concentration in BAL (Post-LPS Challenge)</title>
        <description>Post-LPS challenge CC16 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
        <time_frame>Day 11</time_frame>
        <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2423</title>
            <description>Two 50 mg AZD2423 tablets, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 tablets, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CC16 Concentration in BAL (Post-LPS Challenge)</title>
          <description>Post-LPS challenge CC16 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.</description>
          <population>Thirty-nine patients were included in the efficacy analysis set. Five patients were excluded because they did not have sufficient data to be included in the primary outcome analysis. Four discontinued and one did not complete LPS challenge</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2256" spread="1.132"/>
                    <measurement group_id="O2" value="2589" spread="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD2423 100 mg</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match AZD2423 tablets, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>VASOMOTOR RHINITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institutions or Investigators were permitted to publish or present the study results from their site (or the overall results), providing the article or presentation was submitted to and approved by AstraZeneca beforehand.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Malmgren</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

